Dyadic International vs Eloxx Pharmaceuticals
DYAI and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DYAI and ELOX compare
Eloxx Pharmaceuticals is the larger company, worth 4.1 times as much as Dyadic International ($47.4M against $11.5M).
Dyadic International grew revenue faster over the last twelve months (−7.6% versus −100% for Eloxx Pharmaceuticals).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DYAI | ELOX |
|---|---|---|
| Size and price | ||
| Market cap | $11.5M | $47.4M |
| Share price | $0.316 | $11.74 |
| Change, 1 year | −65.4% | 1067170% |
| Change, 5 years | −91.5% | −98.1% |
| Beta (5Y) | 1.46 | – |
| Employees | 5 | 7 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.7× | – |
| P/B | – | 1.0× |
| Growth | ||
| Revenue growth (TTM) | −7.6% (better) | −100% |
| Revenue growth, 5Y average | 14.0% | – |
| Profitability | ||
| Gross margin | 17.9% | – |
| Operating margin | −237% | – |
| Net margin | −227% | – |
| Return on equity | −47256% | −54.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.69 | 3.74 (better) |
| Altman Z-score | −18.96 | −4.60 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 12.7% | 71.8% |
| Held by insiders | 28.0% | 42.6% |
| Insider net buying, 12 months | −$125K | – |
| Short interest, % of float | 0.32% | 2.3% |
Go deeper
- DYAI stock overview
- DYAI income statement
- DYAI valuation and score
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.